PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 105 | 51-61
Article title

Innovative Thermobalancing therapy can help millions of men with enlarged prostate gland to improve the quality of life and well-being throughout the world

Authors
Content
Title variants
Languages of publication
EN
Abstracts
EN
Millions of men across the world suffer from enlarged prostate or benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms (LUTS). Medications and surgical procedures for BPH have serious side effects, reducing quality of life and wellbeing. 10 years empirical evidence and outcomes of a clinical study have shown effectiveness of innovative Thermobalancing therapy (TT) with Dr Allen’s therapeutic device (DATD) to treat the cause of BPH. Dynamics of urinary symptoms by International Prostate Symptom Score, quality of life (QoL), ultrasound prostate volume (PV mL) and uroflowmetry (maximum flow rate, Qmax mL/s) were evaluated at the beginning and end of the study in 124 patients who received TT for 6 months, comparing with no-treatment group. TT has diminished PV from 45 mL to 31 mL (P<0.001) and the urinary symptoms from 14.2 to 4.9 (P<0.001), increased Qmax 8.1 to 17.7 mL/s (P<0.001) and improved QoL from 3.9 to 1.3(P<0.001). Thus, the obtained data explores the substantial positive changes in PV and urine flow rate and, consequently, the significant improvement of urinary symptoms and QoL after use of TT with DATD as mono-therapy. Given the lack of side effects after use of DATD, which should be expected after BPH drugs and operations, it should be stated that TT should be used worldwide as first line treatment for men with LUTS due to BPH to improve men’s health and wellbeing.
Discipline
Year
Volume
105
Pages
51-61
Physical description
Contributors
author
References
  • [1] Egan KB The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates, Urol Clin North Am 2016, 43(3): 289-97. doi: 10.1016/j.ucl.2016.04.001
  • [2] Speakman M, Kirby R, Doyle S et al Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) – focus on the UK, BJU Int. 2015 Apr; 115(4): 508-19.
  • [3] Kwong PW, Cumming RG, Chan L, Seibel MJ, Naganathan V, Creasey H, Le Couteur D, Waite LM, Sambrook PN, Handelsman D Urinary incontinence and quality of life among older community-dwelling Australian men: the CHAMP study, Age Ageing 2010, 39(3): 349-54. doi: 10.1093/ageing/afq025
  • [4] Lin PH, Freedland SJ, Lifestyle and LUTS: what is the correlation in men? Curr Opin Urol, 2015, 25(1): 1–5.
  • [5] Yassin AA, El-Sakka AI, Saad F, Gooren LJ.: Lower urinary-tract symptoms and testosterone in elderly men, World J Urol, 2008, 26(4): 359-64. doi: 10.1007/s00345-008-0284-x. Epub 2008 Jul 2. Review.
  • [6] Yassin A, Nettleship JE, Talib RA, Almehmadi Y, Doros G. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters, Aging Male, 2016, 19(1): 64-9. doi: 10.3109/13685538.2015.1126573
  • [7] Gacci M, Ficarra V, Sebastianelli A, et al. Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta- Analysis. J Sex Med, 2014, 11: 1554-66
  • [8] Fourcade RO, Lacoin F, Rouprêt М, et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia, World J Urol, 2012, 30: 419-26.
  • [9] Naeem B, Giorgio G, Akshay S. et al Morbidity and Mortality After Benign Prostatic Hyperplasia Surgery: Data from the American College of Surgeons National Surgical Quality Improvement Program, Journal of Endourology, 2014, 28(7): 831-840.
  • [10] Elshal AM, Elmansy HM, Elkoushy MA, Elhilali MM. Male sexual function outcome after three laser prostate surgical techniques: a single center perspective, Urology, 2012, 80: 1098-104.
  • [11] Ingimarsson JP, Isaksson HJ, Sigbjarnarson HP, Gudmundsson J, Geirsson G Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate, Scand J Urol. 2014, 48(1): 73-8. doi: 10.3109/21681805.2013.825878
  • [12] Ishiguro H, Kawahara T Nonsteroidal Anti-Inflammatory Drugs and Prostatic Diseases, BioMed Res. Int. 2014, Article ID 436123, 6 pages http://dx.doi.org/10.1155/2014/436123
  • [13] Kahokehr A, Vather R, Nixon A, Hill AG Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: Systematic review and meta-analysis of randomized controlled trials, BJU Int. 2013, 111, 304–311.
  • [14] Abdulla A, Adams, N, Bone M, Elliott AM, Gaffin, J, Jones D, Knaggs R, Martin D, Sampson L, Schofield P Guidance on the management of pain in older people, Age Ageing 2013, 42, i1–i57.
  • [15] Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications, J Pharm Pharm Sci, 2013, 16 (5): 821-847.
  • [16] Allen S, Aghajanyan IG. Benign Prostatic Hyperplasia Treatment with New Physiotherapeutic Device, Urol J. 2015 14; 12(5): 2371-2376.
  • [17] Allen S, Adjani A Therapeutic Device and Method, United States Patent and Trademark Office, 2016, Patent No: US 9,408,744 B2, https://www.google.com/patents/US9408744
  • [18] Allen S. The Origin of Chronic Diseases Can Be in Capillary Pathology: An Evidence From Clinical Trials on Thermobalancing Treatment of Prostate Reveals, Achievements in the Life Sciences, 2016, 10, 2, 197–202.
  • [19] Allen S, Aghajanyan IG. Use of thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology, Aging Male, 2016 Dec 14:1-5, http://dx.doi.org/10.1080/13685538.2016.1247151
  • [20] Allen S, Aghajanyan IG. Thermobalancing conservative treatment for moderate-to-low-degree lower urinary tract symptoms (LUTS) secondary to prostate enlargement, Cogent Medicine, 2016 3(1), 1195067. http://doi.org/10.1080/2331205X.2016.1195067
  • [21] Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age, J Urol 1984, 132:474–479.
  • [22] McVary KT. BPH: epidemiology and comorbidities, Am J Manag Care, 2006, 12: S122–S128.
  • [23] Gibson W, Wagg A. New horizons: urinary incontinence in older people, Age Ageing, 2014, 43 (2): 157-163.doi: 10.1093/ageing/aft214First
  • [24] Zhang SJ, Qian HN, Zhao Y, et al. Relationship between age and prostate size, Asian Journal of Andrology, 2013, 15, 116–120.
  • [25] Siyal A, Abbasi A, Shaikh SA. Symptoms of benign prostatic hyperplasia: Does prostate size matter? RMJ 2015, 40(3): 286-289.
  • [26] Simon RM, Howard LE, Moreira DM et al. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the reduce trial, Eur Urol. 2015 Dec 24. pii: S0302- 2838(15) 01210-5.
  • [27] American Urological Association (AUA) guideline on the management of Benign Prostatic Hyperplasia, 2015, https://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia
  • [28] Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss, J Sex Med. 2011 Jun; 8(6): 1747-1753.
  • [29] Gubelin HW, Barboza MJ, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia, J Am Acad Dermatol 2014;70: 489–498.e3.
  • [30] Traish AM, Mulgaonkar A, Giordano N. The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression, Korean J Urol. 2014 Jun; 55(6): 367-379.
  • [31] Elshal AM, Elmansy HM, Elkoushy MA et al. Male sexual function outcome after three laser prostate surgical techniques: a single center perspective. Urology, 2012, 80: 1098-1104.
  • [32] Oelke M, Bachmann A, Descazeaud A. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction, Eur Urol. 2013 Jul;64(1): 118-140.
  • [33] Favilla V, Russo GI, Privitera S, Castelli T, Giardina R, Calogero AE, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis, Aging Male, 2016 Sep;19(3): 175-181.
  • [34] Russo GI, Cimino S, Morgia G. Benign prostatic hyperplasia and metabolic syndrome: the expanding evidences of a new disease of aging male, Aging Male, 2015; 18(3): 133-4. doi: 10.3109/13685538.2015.1028353.
  • [35] Shimizu S, Tsounapi P, Shimizu T, Honda M, Inoue K, Dimitriadis F and Saito M. Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: Are these conditions related to vascular dysfunction? 2014, Int J Urol, 21: 856–864. doi:10.1111/iju.12501
  • [36] Pinggera GM, Mitterberger M, Steiner E, et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int. 2008, 102: 470–474.
  • [37] Saito M, Tsounapi P, Oikawa R et al Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH, Sci. Rep, 2014, 4. doi: 10.1038/srep03822
  • [38] Allen S, Aghajanyan IG. Effect of thermobalancing therapy on chronic prostatitis and chronic pelvic pain syndrome, Journal of Clinical Urology, 2016, Sept 20, 1-8, DOI: 10.1177/2051415816671036.
  • [39] Allen, S. The Vascular Factor Plays the Main Role in the Cause of Pain in Men with Chronic Prostatitis and Chronic Pelvic Pain Syndrome: The Results of Clinical Trial on Thermobalancing Therapy. Diseases 2017, 5(4), 25; doi:10.3390/diseases5040025.
  • [40] Puelacher C, Lurati Buse G, Seeberger D, Sazgary L, et al. Perioperative Myocardial Injury After Noncardiac Surgery: Incidence, Mortality, and Characterization. Circulation, 2017; CIRCULATIONAHA.117.030114 DOI: 10.1161/CIRCULATIONAHA.117.030114
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-6022915f-0710-4ca4-a588-6f2f4ae108bf
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.